Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation
- PMID:17573127
- DOI: 10.1016/j.tips.2007.05.003
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation
Abstract
Most smokers repeatedly fail in their attempts to stop smoking because of the addictive nature of the nicotine in tobacco products. Nicotine dependence is probably mediated through the activation of multiple subtypes of neuronal nicotinic acetylcholine receptor (nAChR), among which the mesolimbic alpha(4)beta(2) subtype has a pivotal role. Here, we discuss the rationale for and the design of alpha(4)beta(2) nAChR partial agonists as novel treatments for tobacco addiction. Such agents are expected to exhibit a dual action by sufficiently stimulating alpha(4)beta(2)-nAChR-mediated dopamine release to reduce craving when quitting and by inhibiting nicotine reinforcement when smoking. Potent and selective alpha(4)beta(2) nAChR partial agonists that exhibit dual agonist and antagonist activity in preclinical models can be identified. The validity of this approach is demonstrated by the clinical efficacy of the alpha(4)beta(2) nAChR partial agonist varenicline, which has significantly better quit rates than do other treatments and offers a new option for smoking cessation pharmacotherapy.
Similar articles
- Efficacy and safety of varenicline for smoking cessation.Hays JT, Ebbert JO, Sood A.Hays JT, et al.Am J Med. 2008 Apr;121(4 Suppl 1):S32-42. doi: 10.1016/j.amjmed.2008.01.017.Am J Med. 2008.PMID:18342165Review.
- The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.Foulds J.Foulds J.Int J Clin Pract. 2006 May;60(5):571-6. doi: 10.1111/j.1368-5031.2006.00955.x.Int J Clin Pract. 2006.PMID:16700857Review.
- [New drugs; varenicline].van Bronswijk H, Dubois EA, Zitman FG, Cohen AF.van Bronswijk H, et al.Ned Tijdschr Geneeskd. 2007 Nov 10;151(45):2503-4.Ned Tijdschr Geneeskd. 2007.PMID:18062594Dutch.
- Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.Rollema H, et al.Neuropharmacology. 2007 Mar;52(3):985-94. doi: 10.1016/j.neuropharm.2006.10.016. Epub 2006 Dec 8.Neuropharmacology. 2007.PMID:17157884
- The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.Crunelle CL, Miller ML, Booij J, van den Brink W.Crunelle CL, et al.Eur Neuropsychopharmacol. 2010 Feb;20(2):69-79. doi: 10.1016/j.euroneuro.2009.11.001. Epub 2009 Dec 3.Eur Neuropsychopharmacol. 2010.PMID:19959340Review.
Cited by
- Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.Higgins GA, Silenieks LB, Lau W, de Lannoy IA, Lee DK, Izhakova J, Coen K, Le AD, Fletcher PJ.Higgins GA, et al.Psychopharmacology (Berl). 2013 Apr;226(3):475-90. doi: 10.1007/s00213-012-2919-2. Epub 2012 Nov 25.Psychopharmacology (Berl). 2013.PMID:23184281
- Nicotine Patch Alters Patterns of Cigarette Smoking-Induced Dopamine Release: Patterns Relate to Biomarkers Associated With Treatment Response.Zakiniaeiz Y, Liu H, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Matuskey D, Chen MK, Cosgrove KP, Morris ED.Zakiniaeiz Y, et al.Nicotine Tob Res. 2022 Oct 17;24(10):1597-1606. doi: 10.1093/ntr/ntac026.Nicotine Tob Res. 2022.PMID:35100429Free PMC article.Clinical Trial.
- 86Rb+ efflux mediated by alpha4beta2*-nicotinic acetylcholine receptors with high and low-sensitivity to stimulation by acetylcholine display similar agonist-induced desensitization.Marks MJ, Meinerz NM, Brown RW, Collins AC.Marks MJ, et al.Biochem Pharmacol. 2010 Oct 15;80(8):1238-51. doi: 10.1016/j.bcp.2010.06.040. Epub 2010 Jun 30.Biochem Pharmacol. 2010.PMID:20599770Free PMC article.
- Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients.Xi ZX.Xi ZX.Drug Healthc Patient Saf. 2010 Apr 1;2010(2):39-48. doi: 10.2147/DHPS.S6299.Drug Healthc Patient Saf. 2010.PMID:21278851Free PMC article.
- Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.Quik M, Campos C, Grady SR.Quik M, et al.Biochem Pharmacol. 2013 Oct 15;86(8):1153-62. doi: 10.1016/j.bcp.2013.06.027. Epub 2013 Jul 4.Biochem Pharmacol. 2013.PMID:23831952Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical